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oRIGINAL ARTICLE
Background: The role of surgery in the treatment of non–small-cell 
lung cancer (NSCLC) with clinically manifested mediastinal node 
metastasis is controversial even in resectable cases because it is often 
accompanied by systemic micrometastasis. However, surgery is occa-
sionally indicated for cases with single-station N2 disease or within 
multimodal treatment regimens, and in clinical trials. The aim of this 
study is to evaluate surgical outcomes in a modern cohort of patients 
with clinical (c-) stage IIIA-N2 NSCLC whose nodal metastasis was 
confirmed by pathology (cN2/pN2).
Methods: From the central database of lung cancer patients under-
going surgery in 2004, which was founded by the Japanese Joint 
Committee for Lung Cancer Registration, data of patients having all 
conditions of NSCLC, c-stage IIIA, cN2, and pN2 were extracted, 
and the clinicopathologic profile of patients and surgical outcomes 
were evaluated.
Results: Among 11,663 registered NSCLC cases, 436 patients 
(3.8%) (332 men and 104 women) had been extracted. Their mean 
age was 65 years, and histologic types included adenocarcinoma (n = 
246), squamous cell carcinoma (n = 132), and others (n = 58). The 
proportion of R0 resection was 82.5% and the proportion of the hos-
pital deaths among the cause of death was 2.3%. The 5-year survival 
rate was 30.1% for the selected group of patients. The postoperative 
prognosis was significantly better than those of corresponding popu-
lations extracted from the 1994 (p = 0.0001) and 1999 databases (p 
= 0.0411). Men and women experienced a significantly different sur-
vival outcome (p = 0.025) with 5-year survivals of 27.5% and 37.8%, 
respectively. Single-station N2 cases occupied 60.9 % of the cohort 
and showed a significantly better prognosis than multistation N2 (p = 
0.0053, 35.8 % versus 22.0 % survival rate at 5 years).
Conclusions: The surgical outcomes of c-stage IIIA-cN2/pN2 
NSCLC patients in 2004 were favorable in comparison with those 
ever reported.
Key Words: Non–small-cell lung cancer, Mediastinal node metas-
tasis, Surgery.
(J Thorac Oncol. 2012;7: 850–855)
Surgery is not a generally accepted option for non–small-cell lung cancer (NSCLC) patients with clinically mani-
fested mediastinal lymph node metastasis (cN2/pN2), because 
the presence of N2 metastasis is believed to be indicative of 
systemic disease. In reports published in the 1980s through 
the early 1990s,1–4 surgery for c-stage IIIA-N2 often failed to 
result in local control and was often followed by early appear-
ance of distant metastasis, even after complete resection. 
Since the 1990s, numerous researchers have reported clinical 
trials of induction chemotherapy or chemoradiotherapy fol-
lowed by surgery5–8; however, the role of surgery in the treat-
ment strategy for the disease is still controversial. A recent 
large-scale trial, the North American Intergroup Trial 0139,9 
demonstrated that surgery after induction chemoradiotherapy 
can be beneficial if lobectomy is adequate for complete resec-
tion, although overall survival (the primary end point) in the 
trimodal regimen group was equivalent to that in the chemo-
radiotherapy group. Adjuvant chemotherapy is another poten-
tial option; however, whether cN2/pN2 cases derive the same 
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survival benefit from adjuvant chemotherapy as that reported 
for cN0-1pN2 cases has not yet been clarified.10,11
In Japan, a nationwide database has been managed by 
the Japanese Joint Committee of Lung Cancer Registration 
since 1989. Annual surgical series are collected at 5-year 
intervals, and surgical outcomes have been analyzed and 
reported.12–14 Since then, there has been an increase in the pro-
portions of patients who are women, have stage IA disease 
and adenocarcinoma, and 5-year survival rates have gradually 
improved from 52.6% in 1994,12 to 61.8% in 1999,13 and to 
69.7% in 2004.14 Such results clearly indicate that the clinical 
profile of lung cancers is dramatically changing in Japan. If 
so, and even if progress in radiological work-up biases can-
didates for surgery, the surgical outcomes of a modern series 
of c-stage IIIA-cN2/pN2 NSCLC patients should be reevalu-
ated. In this study, stage III NSCLC patients with clinically 
manifested and pathologically proven N2 were collected from 




In 2010, the Japanese Joint Committee of Lung Cancer 
Registry performed a nationwide retrospective survey for 
primary lung neoplasms resected in 2004. Data from 11,663 
patients who were followed up for 5 years were registered from 
253 teaching hospitals. of these patients, data from those with 
all conditions of histologically confirmed NSCLC, c-stage 
IIIA, cN2, and pN2 were extracted from the master database, 
and the clinicopathologic profiles of patients and surgical out-
comes were evaluated. In addition, the data were compared 
to those of similar populations from the 1994 and 1999 data-
bases. The c-stage and p-stage were determined according to 
the 6th edition of the Union Internationale Contre le Cancer-
TNM staging system,15 and tumor histology was categorized 
according to the World Health organization Classification.16 
A number of mediastinal node stations where metastases were 
recognized by surgical pathology were classified as single- or 
multistation. Each nodal station was determined according to 
Naruke’s map.17
Statistical Analysis
Differences in clinicopathologic demographic variables 
were evaluated by the x2 test or Fisher’s exact test as appropri-
ate. The survival time was defined as time from the date of 
surgery to the date of the last follow-up. The survival curves 
were estimated by the Kaplan-Meier method. Differences in 
survival were assessed by the log-rank test. A multivariate 
analysis for prognostic factors was performed by the Cox pro-
portional hazards regression model. Statistical significance 
was considered to be established when the associated p-value 
was less than 0.05.
TABLE 1. Demographic Data of c-stage IIIA-cN2/pN2 
Patients
Category Number of Patients (%)
Year of 
Registry 2004 1999 1994
Total 436 (100) 823 (100) 580 (100)
Sex
 Male 332 (76.1) 633 (78.0) 438 (75.5)
 Female 104 (23.9) 179 (21.7) 141 (24.3)
 Unknown 11 1
Age (yrs)
 59 107 (24.7) 214 (26.0)a 167 (28.8)b
 60–69 152 (34.9) 321 (39.0) 225 (38.8)
 70–79 156 (35.8) 249 (30.3) 179 (30.9)
 80 21 (4.8) 21 (2.6) 8 (1.4)
 Unknown 18 1
Histologic type
 Adeno 246 (56.4) 458 (55.7)a 291 (50.2)b
 Squ. 132 (30.2) 290 (35.2) 232 (40.0)
 other 58 (13.3) 75 (9.1) 57 (9.8)
cT-factor
 T1 137 (31.4) 183 (22.2)b 112 (19.3)b
 T2 226 (51.8) 490 (59.5) 349 (60.2)
 T3 73 (16.7) 150 (18.2) 119 (20.5)
pT-factor
 T0-1 116 (26.6) 161 (25.0)a 98 (17.0)b
 T2 203 (46.6) 410 (49.8) 286 (49.6)
 T3 68 (15.6) 118 (14.3) 92 (15.9)
 T4 49 (11.2) 123 (14.9) 101 (17.5)
 Unknown 3
Type of surgery
 Pn. 46 (10.6) 115 (14.0)b 114 (19.8)b
 Lob./bilob. 332 (76.1) 656 (80.6) 442 (76.7)
 Sublob. 30 (6.9) 41 (5.0) 20 (3.4)
 other 28 (6.4)c 2 (0.2) 0 (0.0)
 Unknown 11 4
Residual disease
 R0 353 (82.5) 661 (80.3) 443 (77.4)
 R1/2 75 (17.5) 130 (19.7) 120 (21.0)
 Unknown 8 32 17
Perioperative treatment
 Induction 108 
(24.8)d
141 (17.4) 53 (9.1)
 Adjuvante 151 (34.6) — —
 None 137 (31.4) — —
Cause of death
 All 278 (63.8) 539 (65.5) 446 (76.9)
 Hospital 10 (2.3) 30 (3.6) 32 (5.5)
 Lung cancer 241 (55.3) 445 (54.1) 366 (63.1)
 other 27 (6.2)f 59 (7.2) 43 (7.3)
aStatistically significant difference (p < 0.05) compared to 2004.
bStatistically significant difference (p < 0.01) compared to 2004.
cIncludes 20 exploratory thoracotomies.
dEighty-four patients received chemotherapy, 23 received chemoradiotherapy, and 
1 received other radiotherapy.
eThirty-eight patients received oral chemotherapy.
fIncludes deaths related to other cancers (n = 7), deaths related to noncancerous 
disease (n = 18), and deaths with unknown causes (n = 2).
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number of metastasized stations, there was a significant differ-
ence between single-station and multistation N2 patients (p = 
0.0053) with the respective 5-year survival rates being 35.8% 
and 22.0% (Fig. 2C). Five-year survival rates were 28.1% in 
105 patients who received induction treatment, 27.8% in 150 
patients who received adjuvant chemotherapy, and 33.7% in 
137 patients who underwent surgery alone.
DISCUSSION
Surgery is rarely indicated initially for c-stage IIIA-N2 
NSCLC, because the disease is predisposed to possess serious 
local tumor burden and latent systemic disease. Surgery for 
cN2/pN2 resulted in a 5-year survival rate of approximately 
10% 20 to 30 years ago1,2 (Table 2). Reasons for this unfavor-
able prognosis included a high incidence of incomplete resec-
tion because of malignant pleurisy or extra nodal invasion, and 
of early recurrence in distant organs; 5-year survival was only 
20% even in cases of complete resection.3,4 Currently, many 
clinicians regard concurrent chemoradiotherapy as a standard 
care for resectable c-stage IIIA-N2 NSCLC, because a 20% 
5-year survival rate has been achieved even for unresectable 
cases.18,19 In our analysis of the 2004 nationwide registry, 
however, the outcome of 137 patients who underwent surgery 
alone showed 34% 5-year survival rate, which is more favor-
able in comparison with those of the early studies1–4 or com-
parable to those of combined modalities5–9 (Table 2). Although 
retrospectively analyzed, the present data are important as 
they reflect modern surgery results for cN2/pN2 NSCLC. one 
possible explanation for the above results is that selection of 
surgical candidate would have been sophisticated. The 2004 
cohort was also characterized by less advanced T-parameter 
values and a smaller proportion of patients who underwent 
FIGURE 1. Survival curves for c-stage N2/pN2 non–small-
cell lung cancer patients collected from the Japanese Lung 
Cancer Registry in 1994, 1999, and 2004. The postoperative 
5-year survival rates of 554 patients in 1994, 823 patients in 
1999, and 436 patients in 2004 were 19.9%, 24.5%, and 
30.1%, respectively. Significant differences were observed 
between each series by log-rank test; p values were 0.0063 
between 1994 and 1999, <0.0001 between 1994 and 2004, 
and 0.0411 between 1999 and 2004.
RESULTS
Patient Profiles
Among 11,663 registered lung cancer patients, 800 cases 
of c-stage IIIA/ cN2/NSCLC were included. of them, p-N0, 
1, 2, and 3 were 271, 75, 436, and 18 patients, respectively, 
and the 436 cN2/pN2 patients were analyzed in this study. 
Patients with single- and multistation N2 were 235 and 151, 
respectively, and no information was available in the other 34. 
Demographic data for the patients are summarized in Table 1. 
These patients represented 3.8% of all 11,423 NSCLC patients 
in the 2004 registry, and comprised 332 men and 104 women. 
The mean age was 65.0 years, and 40.6% of patients were 70 
years old or more. Histologic types include adenocarcinoma 
(n = 246), squamous cell carcinoma (n = 132), large cell car-
cinoma (n = 23), adenosquamous cell carcinoma (n = 17), and 
others (n = 18). Induction treatments such as chemotherapy 
and chemoradiotherapy were administered to 108 patients 
(24.8%), and adjuvant chemotherapy including oral tegafur/
uracil was given to 151 patients (34.6%). Surgical procedures 
included pneumonectomy (n = 46), lobectomy/bilobectomy 
(n = 332), sublobar resection (n = 30), and exploratory tho-
racotomy (n = 20); R0 surgery was achieved in 361 patients 
(82.5%). overall, 278 patients died during the 5-year follow-
up period. of these, 10 deaths (2.3%) occurred in the hospital 
after surgery and 6 deaths (1.4%) occurred within 30 days after 
surgery. Patient profiles were compared to those of patients 
with the same disease stage from previous registry data (Table 
1). A total of 540 and 823 patients were collected from the 
1994 and 1999 databases, respectively, which represented 
6.5% and 8.7% of the entire registry population, respectively. 
The 2004 cohort was characterized by a larger proportion of 
adenocarcinoma, more advanced age, less advanced clinical 
and pathologic T factors, and less pneumonectomy. In fact, 
the proportion of patients who underwent pneumonectomy 
in 2004 was almost half that of 1994. The R0 surgery rate 
tended to increase, but not to a statistically significant degree. 
Although statistical analysis could not be performed for “peri-
operative treatment” because adjuvant chemotherapy data 
were not collected until 1999, the proportion of patients who 
underwent induction treatment tended to increase.
Survival
The overall 5-year survival rate in the 2004 cohort 
was 30.1%, whereas that of 1994 and 1999 was 19.9% and 
24.5%, respectively. When the survival curves were compared, 
the 2004 cohort was significantly better than the 1994 (p = 
0.0001) and 1999 cohorts (p = 0.0411) (Fig. 1). The 5-year 
survival rates were 33.4% in 353 patients with R0 surgery, 
21.7% in 24 patients with R1 surgery, and 0.0% in 51 patients 
with R2 surgery. The differences in survival between the R1 
group and R2 groups and also between the R0 and R2 groups 
were statistically significant (p = 0.0098 and p < 0.0001, 
respectively), whereas no significant difference was found 
between the R0 and R1 groups (p = 0.6423) (Fig. 2A). The 
5-year survival rate was for 27.5% for men was and 37.8% 
for women. The survival experience was significantly bet-
ter for women than for men (p = 0.025) (Fig. 2B). As to the 
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pneumonectomy. In 2004, 10.4% of the patients underwent 
pneumonectomy, compared to 14.0% in 1999 and 20.0% in 
1994; thus, it seems that even among cN2/pN2 cases, less 
advanced cases were selected for surgery. The decreased rate 
of pneumonectomy may result in decreased hospital mortality. 
Actually, the series of the Japanese nationwide registry clearly 
revealed a time trend for improved survival of the stage IIIA-
cN2/pN2 disease (Fig. 1). Several types of N2 cases, such as 
single-station or single-node N2 cases, have experienced a 
good prognosis after surgery.20,21 The Japan Clinical oncology 
Group conducted a questionnaire study regarding outcomes 
in stage IIIA-pN2 patients who underwent complete resection 
from 1992 to 1993.21 Five-year survival rates were 31% for 
all pN2 cases, 27% for cN2 cases, and 43% for single-station 
N2 cases. In our series, the 5-year survival rate of single-sta-
tion pN2 was also significantly higher than that of multista-
tion pN2, and a proportion of single-station pN2 was 61 % in 
this study that was relatively higher than 52 % of the Japan 
Clinical oncology Group study, which suggests that such a 
single-station N2 was likely to be selected for surgery in Japan 
of 2004.
Increase of adenocarcinoma may be another reason 
for the surgical results because the histology is associated 
with favorable prognosis.13,14 Thus, recent cN2/pN2 NSCLC 
FIGURE 2. Survival curves for subpopulations of c-stage N2/pN2 non–small-cell lung cancer patients from the 2004 registry. 
A, Male and female survival curves. The 5-year survival rates were 27.5% in 324 males and 37.8% in 104 females; this difference 
was statistically significant (p = 0.0245). B, Subpopulations categorized by level of residual disease. The 5-year survival rates 
were 33.4% in 353 R0 patients, 21.7% in 24 R1 patients, and 0.0% in 51 R2 patients; the differences between R1 patients and 
R2 (p = 0.0098) and between R0 and R2 patients (p < 0.0001) were statistically significant, whereas no significant difference 
was observed between R0 and R1 patients (p = 0.6423). C, Single- and multistations N2. The 5-year survival rates were 35.8% 
in 235 patients with single-station N2 and 22.0% in 151 with multistation N2; this difference was statistically significant  
(p = 0.0053).
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patients who undergo surgery are distinct from the cN2/pN2 
NSCLC population of previous decades. often, improvements 
in diagnostic facilities outpace changes in treatment outcomes, 
and such a transition of the medical environment may always 
influence the changes in patient selection and characteristics.
With respect to surgery alone, the present data are much 
valuable because cN2/pN2 is now usually contraindicated for 
surgery alone and the surgical outcome of modern series has 
been rarely presented. In our study, data of 137 patients with 
stage IIIA-cN2/pN2 patients treated by surgery alone in the 
particular period (2004) were retrospectively collected from 
the large-scale registry, and the relatively favorable outcome 
was revealed. Although the detailed reasons for surgical indi-
cation was unknown, they might be highly selected or might 
have unusual surgical indication because these cases only rep-
resented 1.2% of all resected NSCLC cases; therefore, surgery 
alone cannot yet be recommended as a treatment option in 
practice.
Although the prognosis of patients in the present study 
was superior to those previously reported, it remains unsatis-
factory, especially considering that the majority of the patients 
underwent perioperative therapies. Whether or not induction 
therapy followed by surgery provides a survival benefit for 
resectable cN2/pN2 NSCLC patients has been the focus of 
much attention. Two meta-analyses of induction chemother-
apy reported22,23 demonstrated significance or tendency of 
favor of induction chemotherapy for stage III NSCLC; how-
ever, those analyses included two controversial studies. In the 
randomized trials conducted in the 1990s,5,6 there was signifi-
cant efficacy of neoadjuvant platinum-based chemotherapy in 
this patient population (Table 2); however, the results have not 
been widely accepted because of far lower survival of patients 
in the surgery-alone groups. Concurrent chemoradiotherapy 
as induction has been expected to be a more promising strat-
egy for fit cases7,8,24 (Table 2). Compared to chemotherapy, 
chemoradiotherapy results in better local control and a higher 
incidence of downstaging, which is a strong indicator of effi-
cacy. In the present series, induction therapy was administered 
to 108 patients (24.8%), 84 of whom received chemotherapy 
and 23 received chemoradiotherapy; however, survival of these 
patients was equivalent to that of patients who underwent sur-
gery alone. These results may be explained by the fact that 
the downstaged cases were automatically excluded from the 
present cohort through the retrospective selection of cN2/pN2 
cases, and may also show that survival benefit of induction 
therapies was hardly recognized in non-downstaged cases. 
Taking into account that the indication of induction treatments 
could not be clarified in this retrospective study, no conclusion 
can be drawn for this issue.
The North America Intergroup Trial 0139, which com-
pared concurrent chemoradiation followed by surgery (trimodal 
therapy) versus definitive chemoradiation (bimodal therapy) 
for resectable c-stage IIIA-N2 cases,9 importantly revealed 
that no difference in overall survival occurred between the 
two treatment arms, although patients in the trimodal-therapy 
arm experienced superior recurrence-free survival. However, 
in a retrospective matched-cohort analysis, trimodal-therapy 
patients who underwent lobectomy experienced significantly 
better survival than bimodal-therapy patients who were 
selected by matching age, sex, performance status, and cT fac-
tor; thus, trimodal therapy was suggested to be effective for fit 
patients. Uy et al.25 reported that in a study in which 40 out of 
550 c-stage IIIA-N2 referrals received trimodal therapy in a 
community practice using the same regimen as that used in the 
North America Intergroup Trial 0139 (cisplatin/etoposide/45 
Gy), the R0 resection rate was 92.5% and the 3-year overall 
TABLE 2. Historical Profile of Surgical Results for cN2/pN2 NSCLC
Report Dates Combined Modality Number of Patients Rate of R0 (%) Rate of 5-year Survival (%)
Pearson et al.1 1964–1980 Induction R. 79 65 9
Martini and Flehinger2 1974–1981 Adjuvant R 179 (only CR) — 18
Funatsu et al.4 1970–1989 S alone 91a 14 6
Watanabe et al.3 1980–1990 S alone 106a 50 16
Roth et al.5 1987–1993 Induction C 28 61 56 (at 3 years)
S alone 30 66 19 (at 3 years)
Rosell et al.6 1989–1991 Induction C 30 85 25 (at 2 years)
Adjuvant R 30 90 0 (at 2 years)
Choi et al.8 1988–1995 Induction CR (R: twice daily) 42 81 37
Ichinose21 1992–1993 S alone or S first 164 (only CR) — 27
Albain et al.9 1994–2001 Induction CR 202 71 27
Definite CR 194 20
Uy et al.25 1997–2004 Induction CR 40 93 52 (at 3 years)
Present 2004 Various (all) 436 83 30
 Single 235 36
 Multi151 22
Adjuvant C 151 28
Induction C/CR 108 28
S alone 137 34
aCases with exploratory thoracotomy were excluded from the study.
R, Radiation; C, chemotherapy; S, surgery; CR, chemoradiation; Single, single-station N2; Multi, multistation N2; NSCLC, non–small-cell lung cancer.
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and disease-free survival rates both exceeded 50%. The above 
results indicate that induction treatments with chemoradiation 
could enhance the role of surgery for the disease if patients are 
properly selected.
Recent clinical trials have revealed that adjuvant cis-
platin doublets increase postoperative 5-year survival rates 
by 15% in postoperative stage IIIA-N2 NSCLC cases10,11; 
however, no information regarding the c-stage of such cases 
was reported. In the present study, 151 patients who received 
adjuvant chemotherapy experienced a survival rate similar to 
the 137 patients who underwent surgery alone. In this retro-
spective study, however, indication of adjuvant therapy was 
not clarified for each case; hence, no conclusions about the 
efficacy of adjuvant therapy for c-stage IIIA-cN2/pN2 were 
determined.
Despite several limitations, this large nationwide data-
base study has demonstrated the finding of a modern surgi-
cal outcome for selected patients with stage IIIA-cN2/pN2 
NSCLC, and that the postoperative survival was favorable in 
comparison with those previously reported.
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